Novo Nordisk A/S (NVO) EV/Assets Ratio: 2.47x
Is Novo Nordisk A/S’s EV/Assets ratio high or low?
Novo Nordisk A/S's EV/Assets ratio of 2.47x is 93% below its 5-year average of 33.14x, near the low end of its 5-year range (2.04x–84.96x).
As of Wednesday, June 17, 2026. 19.05% below its 12-month average of 3.05x.
NVO EV/Assets Ratio Chart
NVO Average EV/Assets Ratio Chart
NVO Current vs Average EV/Assets Ratio Chart
NVO EV/Assets Ratio Metrics
EV/ASSETS RATIO
2.47x
EV/ASSETS RATIO AVG TTM
3.05x
EV/ASSETS RATIO AVG 3Y
23.74x
EV/ASSETS RATIO AVG 5Y
33.14x
EV/ASSETS RATIO AVG 10Y
26.31x
EV/ASSETS RATIO AVG 15Y
20.47x
EV/ASSETS RATIO AVG 20Y
6.69x
CURRENT VS TTM AVG
-19.05%
CURRENT VS 3Y AVG
-89.59%
CURRENT VS 5Y AVG
-92.55%
CURRENT VS 10Y AVG
-90.61%
CURRENT VS 15Y AVG
-87.93%
CURRENT VS 20Y AVG
-63.07%
NVO Competitors' EV/Assets Ratio
| NAME | MARKET CAP | EV/ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Novo Nordisk A/S (NVO) | $193.53B | 2.47x | 3.05x | 23.74x | 33.14x |
| Amgen Inc. (AMGN)vs › | $187.59B | 2.54x | 2.47x | 2.27x | 2.38x |
| Thermo Fisher Scientific Inc. (TMO)vs › | $175.64B | 1.91x | 2.16x | 2.33x | 2.57x |
| Gilead Sciences, Inc. (GILD)vs › | $158.06B | 3.09x | 3.06x | 2.44x | 2.16x |
| Abbott Laboratories (ABT)vs › | $157.84B | 1.68x | 2.48x | 2.67x | 2.75x |
| Pfizer Inc. (PFE)vs › | $148.41B | 1.02x | 1.00x | 1.03x | 1.28x |
| Intuitive Surgical, Inc. (ISRG)vs › | $145.70B | 7.36x | 8.84x | 9.09x | 8.49x |
| Danaher Corporation (DHR)vs › | $128.06B | 1.70x | 1.98x | 2.16x | 2.26x |
| CVS Health Corporation (CVS)vs › | $127.73B | 0.78x | 0.67x | 0.63x | 0.70x |
| Stryker Corporation (SYK)vs › | $119.06B | 2.86x | 3.26x | 3.42x | 3.27x |
Novo Nordisk A/S EV/Assets Ratio Formula & Definition
EV/Assets compares enterprise value to total assets. It is useful for asset-heavy businesses and for comparing how much the market pays for each dollar of assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Novo Nordisk A/S EV/Assets Ratio FAQ
- What is the EV/Assets ratio for Novo Nordisk A/S (NVO)?
- The EV/Assets ratio for NVO stock is 2.47x.
- Is Novo Nordisk A/S's EV/Assets ratio high or low?
- Novo Nordisk A/S's EV/Assets ratio of 2.47x is 93% below its 5-year average of 33.14x, near the low end of its 5-year range (2.04x–84.96x).
- What is the TTM average EV/Assets ratio for Novo Nordisk A/S (NVO)?
- The TTM average EV/Assets ratio for NVO stock is 3.05x.
- What is the 3Y average EV/Assets ratio for Novo Nordisk A/S (NVO)?
- The 3Y average EV/Assets ratio for NVO stock is 23.74x.
- What is the 5Y average EV/Assets ratio for Novo Nordisk A/S (NVO)?
- The 5Y average EV/Assets ratio for NVO stock is 33.14x.
- What is the 10Y average EV/Assets ratio for Novo Nordisk A/S (NVO)?
- The 10Y average EV/Assets ratio for NVO stock is 26.31x.
- What is the 15Y average EV/Assets ratio for Novo Nordisk A/S (NVO)?
- The 15Y average EV/Assets ratio for NVO stock is 20.47x.
- What is the 20Y average EV/Assets ratio for Novo Nordisk A/S (NVO)?
- The 20Y average EV/Assets ratio for NVO stock is 6.69x.
Novo Nordisk A/S EV/Assets Ratio History
| DATE | EV/ASSETS RATIO |
|---|---|
| 2026-06-16 | 2.47x |
| 2026-06-15 | 2.49x |
| 2026-06-12 | 2.49x |
| 2026-06-11 | 2.49x |
| 2026-06-10 | 2.43x |
| 2026-06-09 | 2.40x |
| 2026-06-08 | 2.34x |
| 2026-06-05 | 2.44x |
| 2026-06-04 | 2.48x |
| 2026-06-03 | 2.39x |
| 2026-06-02 | 2.44x |
| 2026-06-01 | 2.50x |
| 2026-05-29 | 2.58x |
| 2026-05-28 | 2.57x |
| 2026-05-27 | 2.52x |
| 2026-05-26 | 2.50x |
| 2026-05-22 | 2.54x |
| 2026-05-21 | 2.51x |
| 2026-05-20 | 2.55x |
| 2026-05-19 | 2.51x |
| 2026-05-18 | 2.51x |
| 2026-05-15 | 2.53x |
| 2026-05-14 | 2.59x |
| 2026-05-13 | 2.65x |
| 2026-05-12 | 2.65x |
| 2026-05-11 | 2.62x |
| 2026-05-08 | 2.60x |
| 2026-05-07 | 2.59x |
| 2026-05-06 | 2.58x |
| 2026-05-05 | 2.54x |
| 2026-05-04 | 2.51x |
| 2026-05-01 | 2.48x |
| 2026-04-30 | 2.40x |
| 2026-04-29 | 2.30x |
| 2026-04-28 | 2.34x |
| 2026-04-27 | 2.34x |
| 2026-04-24 | 2.34x |
| 2026-04-23 | 2.20x |
| 2026-04-22 | 2.24x |
| 2026-04-21 | 2.25x |
| 2026-04-20 | 2.31x |
| 2026-04-17 | 2.31x |
| 2026-04-16 | 2.33x |
| 2026-04-15 | 2.32x |
| 2026-04-14 | 2.25x |
| 2026-04-13 | 2.18x |
| 2026-04-10 | 2.15x |
| 2026-04-09 | 2.15x |
| 2026-04-08 | 2.16x |
| 2026-04-07 | 2.12x |
| 2026-04-06 | 2.11x |
| 2026-04-02 | 2.12x |
| 2026-04-01 | 2.10x |
| 2026-03-31 | 2.11x |
| 2026-03-30 | 2.04x |
| 2026-03-27 | 2.07x |
| 2026-03-26 | 2.09x |
| 2026-03-25 | 2.09x |
| 2026-03-24 | 2.12x |
| 2026-03-23 | 2.12x |
| 2026-03-20 | 2.10x |
| 2026-03-19 | 2.13x |
| 2026-03-18 | 2.15x |
| 2026-03-17 | 2.20x |
| 2026-03-16 | 2.21x |
| 2026-03-13 | 2.17x |
| 2026-03-12 | 2.18x |
| 2026-03-11 | 2.22x |
| 2026-03-10 | 2.21x |
| 2026-03-09 | 2.27x |
| 2026-03-06 | 2.21x |
| 2026-03-05 | 2.23x |
| 2026-03-04 | 2.20x |
| 2026-03-03 | 2.11x |
| 2026-03-02 | 2.16x |
| 2026-02-27 | 2.15x |
| 2026-02-26 | 2.16x |
| 2026-02-25 | 2.19x |
| 2026-02-24 | 2.21x |
| 2026-02-23 | 2.26x |
| 2026-02-20 | 2.67x |
| 2026-02-19 | 2.72x |
| 2026-02-18 | 2.76x |
| 2026-02-17 | 2.77x |
| 2026-02-13 | 2.78x |
| 2026-02-12 | 2.75x |
| 2026-02-11 | 2.74x |
| 2026-02-10 | 2.76x |
| 2026-02-09 | 2.77x |
| 2026-02-06 | 2.68x |
| 2026-02-05 | 2.46x |
| 2026-02-04 | 2.66x |
| 2026-02-03 | 2.82x |
| 2026-02-02 | 3.40x |
| 2026-01-30 | 3.42x |
| 2026-01-29 | 3.42x |
| 2026-01-28 | 3.47x |
| 2026-01-27 | 3.62x |
| 2026-01-26 | 3.68x |
| 2026-01-23 | 3.58x |
| 2026-01-22 | 3.58x |
| 2026-01-21 | 3.42x |
| 2026-01-20 | 3.49x |
| 2026-01-16 | 3.59x |
| 2026-01-15 | 3.30x |
| 2026-01-14 | 3.40x |
| 2026-01-13 | 3.44x |
| 2026-01-12 | 3.45x |
| 2026-01-09 | 3.39x |
| 2026-01-08 | 3.31x |
| 2026-01-07 | 3.27x |
| 2026-01-06 | 3.25x |
| 2026-01-05 | 3.19x |
| 2026-01-02 | 3.04x |
| 2025-12-31 | 2.95x |
| 2025-12-30 | 2.97x |
| 2025-12-29 | 2.98x |
| 2025-12-26 | 3.04x |
| 2025-12-24 | 3.04x |
| 2025-12-23 | 2.99x |
| 2025-12-22 | 2.80x |
| 2025-12-19 | 2.80x |
| 2025-12-18 | 2.77x |
| 2025-12-17 | 2.78x |
| 2025-12-16 | 2.85x |
| 2025-12-15 | 2.92x |
| 2025-12-12 | 2.91x |
| 2025-12-11 | 2.92x |
| 2025-12-10 | 2.85x |
| 2025-12-09 | 2.70x |
| 2025-12-08 | 2.72x |
| 2025-12-05 | 2.78x |
| 2025-12-04 | 2.79x |
| 2025-12-03 | 2.77x |
| 2025-12-02 | 2.76x |
| 2025-12-01 | 2.82x |
| 2025-11-28 | 2.87x |
| 2025-11-26 | 2.83x |
| 2025-11-25 | 2.74x |
| 2025-11-24 | 2.62x |
| 2025-11-21 | 2.77x |
| 2025-11-20 | 2.77x |
| 2025-11-19 | 2.85x |
| 2025-11-18 | 2.77x |
| 2025-11-17 | 2.82x |
| 2025-11-14 | 2.81x |
| 2025-11-13 | 2.86x |
| 2025-11-12 | 2.92x |
| 2025-11-11 | 2.86x |
| 2025-11-10 | 2.68x |
| 2025-11-07 | 2.66x |
| 2025-11-06 | 2.71x |
| 2025-11-05 | 2.82x |
| 2025-11-04 | 2.99x |
| 2025-11-03 | 3.04x |
| 2025-10-31 | 3.06x |
| 2025-10-30 | 3.10x |
| 2025-10-29 | 3.18x |
| 2025-10-28 | 3.21x |
| 2025-10-27 | 3.26x |
| 2025-10-24 | 3.27x |
| 2025-10-23 | 3.28x |
| 2025-10-22 | 3.29x |
| 2025-10-21 | 3.37x |
| 2025-10-20 | 3.43x |
| 2025-10-17 | 3.35x |
| 2025-10-16 | 3.45x |
| 2025-10-15 | 3.49x |
| 2025-10-14 | 3.48x |
| 2025-10-13 | 3.53x |
| 2025-10-10 | 3.50x |
| 2025-10-09 | 3.60x |
| 2025-10-08 | 3.66x |
| 2025-10-07 | 3.62x |
| 2025-10-06 | 3.66x |
| 2025-10-03 | 3.66x |
| 2025-10-02 | 3.61x |
| 2025-10-01 | 3.63x |
| 2025-09-30 | 3.42x |
| 2025-09-29 | 3.42x |
| 2025-09-26 | 3.42x |
| 2025-09-25 | 3.45x |
| 2025-09-24 | 3.61x |
| 2025-09-23 | 3.65x |
| 2025-09-22 | 3.72x |
| 2025-09-19 | 3.76x |
| 2025-09-18 | 3.79x |
| 2025-09-17 | 3.58x |
| 2025-09-16 | 3.52x |
| 2025-09-15 | 3.42x |
| 2025-09-12 | 3.38x |
| 2025-09-11 | 3.35x |
| 2025-09-10 | 3.35x |
| 2025-09-09 | 3.35x |
| 2025-09-08 | 3.35x |
| 2025-09-05 | 3.40x |
| 2025-09-04 | 3.45x |
| 2025-09-03 | 3.49x |
| 2025-09-02 | 3.47x |
| 2025-08-29 | 3.47x |
| 2025-08-28 | 3.45x |
| 2025-08-27 | 3.47x |
| 2025-08-26 | 3.41x |
| 2025-08-25 | 3.47x |
| 2025-08-22 | 3.50x |
| 2025-08-21 | 3.41x |
| 2025-08-20 | 3.35x |
| 2025-08-19 | 3.37x |
| 2025-08-18 | 3.31x |
| 2025-08-15 | 3.24x |
| 2025-08-14 | 3.15x |
| 2025-08-13 | 3.15x |
| 2025-08-12 | 3.08x |
| 2025-08-11 | 3.09x |
| 2025-08-08 | 3.16x |
| 2025-08-07 | 3.02x |
| 2025-08-06 | 2.82x |
| 2025-08-05 | 3.13x |
| 2025-08-04 | 3.23x |
| 2025-08-01 | 3.19x |
| 2025-07-31 | 3.12x |
| 2025-07-30 | 3.30x |
| 2025-07-29 | 3.55x |
| 2025-07-28 | 4.49x |
| 2025-07-25 | 4.66x |
| 2025-07-24 | 4.60x |
| 2025-07-23 | 4.56x |
| 2025-07-22 | 4.35x |
| 2025-07-21 | 4.24x |
| 2025-07-18 | 4.20x |
| 2025-07-17 | 4.26x |
| 2025-07-16 | 4.37x |
| 2025-07-15 | 4.38x |
| 2025-07-14 | 4.49x |
| 2025-07-11 | 4.49x |
| 2025-07-10 | 4.62x |
| 2025-07-09 | 4.53x |
| 2025-07-08 | 4.53x |
| 2025-07-07 | 4.51x |
| 2025-07-03 | 4.50x |
| 2025-07-02 | 4.54x |
| 2025-07-01 | 4.54x |
| 2025-06-30 | 4.49x |
| 2025-06-27 | 4.46x |
| 2025-06-26 | 4.41x |
| 2025-06-25 | 4.39x |
| 2025-06-24 | 4.60x |
| 2025-06-23 | 4.54x |
| 2025-06-20 | 4.79x |
| 2025-06-18 | 4.81x |
| 2025-06-17 | 4.83x |
| 2025-06-16 | 4.99x |
| 2025-06-13 | 5.17x |
| 2025-06-12 | 5.25x |
| 2025-06-11 | 5.10x |
| 2025-06-10 | 5.14x |
| 2025-06-09 | 4.90x |
| 2025-06-06 | 4.84x |
| 2025-06-05 | 4.72x |
| 2025-06-04 | 4.68x |
Showing the most recent 260 of 5,031 data points. The chart above shows the full history.
Related Metrics
About Novo Nordisk A/S
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Maziar Mike Doustdar